Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Medtronic (MDT) announced its intent to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) therapies for chronic pain management. This acquisition is expected to expand Medtronic's pain therapy portfolio, which already includes spinal cord stimulation and nerve ablation, to meet the growing demand for non-opioid pain relief. The deal, valued at approximately $650 million, aims to strengthen Medtronic's neuromodulation capabilities and support more patients with minimally invasive options.
Medtronic to create European software hub in Ireland
Medtronic is establishing a European software hub in Galway, Ireland, focused on developing cloud-based platforms and clinical software for cardiac patients with implanted devices. This investment will initially create 85 jobs, with further growth anticipated over the next three years. The move expands Medtronic's presence in Ireland, where it already has its corporate headquarters, and reflects a broader strategy including a global AI and robotics hub in London, and consolidation of cardiology businesses.
Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story
Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures, expanding its urologic stone management portfolio in the United States. This launch tests the company's execution capabilities amidst a mixed stock performance, a microbiology pouch recall, and new leadership in BD Interventional. Investors will be watching the adoption rate of the Elyra system and the company's ability to maintain product reliability and address its debt levels.
Intuitive readies 100 updates and improvements for da Vinci 5
Intuitive is preparing to roll out over 100 updates and user experience improvements for its da Vinci 5 surgical robot, starting in June in the U.S. These enhancements aim to boost communication between remote and on-site physicians, simplify access, and improve educational opportunities. The updates also include increasing the number of uses for several force-feedback instruments, which could reduce per-procedure costs amidst growing competition in the robotic surgery market.
Pzena Investment Management LLC Reduces Stock Holdings in Medtronic PLC $MDT
Pzena Investment Management LLC significantly cut its stake in Medtronic PLC by 45.7% in the fourth quarter, selling over 2.7 million shares but still holding 3.22 million shares valued at approximately $309.2 million. Medtronic is receiving mixed analyst sentiment, with some downgrades and lower price targets, despite a "Moderate Buy" consensus and an average target price of $106.45. The company recently announced a $650 million acquisition of SPR Therapeutics to expand its chronic pain neuromodulation portfolio, a move that has drawn some market concerns regarding costs and execution risks.
How syringe-maker BD is using AI to stay sharp
Becton Dickinson (BD), a leading medical device company, is integrating AI and automation with "lean manufacturing" principles to boost efficiency and innovation. CEO Tom Polen has implemented the BD Excellence program, which combines Toyota's continuous improvement methods with AI vision systems and robotics to optimize production and reduce waste. The strategy aims to empower employees, enhance productivity, and reposition BD for future growth beyond traditional medical devices into areas like AI sensors and regenerative medicine.
Global Retirement Partners LLC Increases Stake in Medtronic PLC $MDT
Global Retirement Partners LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 54.6% in the fourth quarter, bringing its total holdings to 51,919 shares valued at $4.99 million. This move is part of a broader trend of institutional investors raising their positions in Medtronic, which now has 82.06% of its stock owned by hedge funds and other institutional investors. Despite mixed analyst ratings, with a "Moderate Buy" consensus and an average price target of $106.45, Medtronic continues to demonstrate strong financial performance, reporting $1.36 EPS against an estimated $1.34 and a revenue increase of 5.8% year-over-year.
Latham Advises SPR Therapeutics in Acquisition by Medtronic
Latham & Watkins LLP advised SPR Therapeutics Inc. in its acquisition by Medtronic plc for approximately US$650 million. SPR Therapeutics is a leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction is subject to customary closing conditions and regulatory approvals.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. stock exhibited a strong performance on a recent trading day, closing higher and outperforming its competitors. The stock also surpassed the S&P 500 in daily gains.
Medtronic to acquire Cleveland medical tech leader SPR Therapeutics for $650 Million
Medtronic (NYSE: MDT) is set to acquire Cleveland-based SPR Therapeutics Inc. for an upfront cash payment of approximately $650 million. This acquisition will integrate SPR's FDA-cleared SPRINT Peripheral Nerve Stimulation (PNS) System, a temporary non-opioid pain therapy, into Medtronic's neuromodulation portfolio. The deal highlights a significant win for Northeast Ohio's biomedical sector and strengthens Medtronic's offerings in minimally invasive chronic pain treatments.
Medtronic to acquire SPR Therapeutics for $650m
Medtronic is set to acquire SPR Therapeutics for approximately $650 million, enhancing its offerings in peripheral nerve stimulation (PNS) for chronic pain management. This acquisition will integrate SPR's SPRINT PNS System, an FDA-cleared temporary therapy, into Medtronic's neuromodulation solutions. The deal aims to provide earlier intervention options for chronic pain patients and is expected to close in the first half of Medtronic's fiscal year 2027.
IFP Advisors Inc Boosts Stake in Medtronic PLC $MDT
IFP Advisors Inc increased its stake in Medtronic PLC by 33.4% in the fourth quarter, now owning 57,287 shares valued at $5,503,000. Other institutional investors also adjusted their positions in Medtronic, which has a current market cap of $100.26 billion and recently announced a quarterly dividend. The medical technology company's stock is trading down 0.6% and has received a "Moderate Buy" consensus rating from analysts.
Buying pulsed field ablation systems: What hospitals should know
The article discusses factors hospitals should consider when purchasing pulsed field ablation systems due to the crowded market. It lists several companies offering these systems, including Boston Scientific, Abbott, Medtronic, Johnson & Johnson MedTech, and Kardium Inc. The piece is part of a series covering medical devices.
Fast-growing Cleveland biotech firm SPR Therapeutics sold for $650M to Irish company
Cleveland-based biotech company SPR Therapeutics has been sold for $650 million to an unnamed Irish company. This acquisition highlights a significant transaction in the healthcare sector, particularly for a fast-growing firm. The deal was announced on May 20, 2026.
Medtronic to buy SPR Therapeutics for about $650M
Medtronic announced its agreement to acquire SPR Therapeutics for $650 million in cash, marking its third major acquisition this year. This deal will expand Medtronic's neuromodulation business by adding SPR Therapeutic's Sprint peripheral nerve stimulation device, which treats chronic pain without requiring a permanent implant. The acquisition is expected to close within the first half of Medtronic's 2027 fiscal year, pending regulatory approvals.
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services has announced that it has fully restored operations after a cybersecurity attack earlier this month. The company does not anticipate any material impact on its 2026 financial outlook and continues its investigation, having found no further unauthorized access. Analysts are encouraged by the company's quick return to normal operations and ability to offset disruptions.
Medtronic data back renal denervation in the long term
Medtronic presented new analyses at EuroPCR showing that its Symplicity Spyral renal denervation system significantly reduced blood pressure in patients over three years. One study involved 787 patients with prior cardiovascular events, and another followed 903 people with severe hypertension. These findings support renal denervation as a device-based option for hypertension, adding to evidence gathered since the system received FDA approval in late 2023.
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026
This article examines three high-yield healthcare stocks—Pfizer, AbbVie, and Medtronic—detailing their unique dividend profiles and business models for income investors looking at 2026. Pfizer offers the highest yield with business challenges, AbbVie presents a balanced growth story with new drug successes, and Medtronic stands out for its consistent dividend history as a medical technology company. Each company provides a different risk-reward proposition driven by factors such as patent expirations, new drug pipelines, and market stability.
Medtronic stock rises as company acquires SPR Therapeutics for $650M
Medtronic PLC announced its plan to acquire privately held SPR Therapeutics for approximately $650 million in cash. This acquisition will expand Medtronic's portfolio of chronic pain treatments by adding SPR's non-opioid, non-surgical SPRINT system. The deal is expected to close in the first half of Medtronic's fiscal year 2027, subject to regulatory approvals.
Medtronic stock rises as company acquires SPR Therapeutics for $650M
Medtronic PLC announced its plan to acquire privately held SPR Therapeutics for approximately $650 million in cash, expanding its offerings for chronic pain treatment. The acquisition will allow Medtronic to incorporate SPR's SPRINT system, a non-opioid, non-surgical therapy for pain relief, into its portfolio. The deal, which aims to provide less invasive pain relief options to more patients, is expected to finalize in the first half of Medtronic’s fiscal 2027, pending regulatory approvals.
Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options
Medtronic announced its intention to acquire SPR Therapeutics for approximately $650 million in cash. This acquisition will expand Medtronic's offerings in chronic pain treatment by adding SPR's SPRINT system, a non-opioid, minimally invasive therapy. The deal is expected to close in the first half of Medtronic's fiscal year 2027, pending regulatory approvals.
Medtronic stock rises as company acquires SPR Therapeutics for $650M
Medtronic PLC announced its plan to acquire SPR Therapeutics for approximately $650 million in cash, aiming to expand its portfolio of chronic pain treatments. This acquisition will grant Medtronic access to SPR's SPRINT system, a 60-day therapy for pain relief that does not require a permanent implant. The deal is expected to close in the first half of Medtronic's fiscal year 2027, subject to regulatory approvals.
Medtronic to spend $650M on 60-day nerve therapy for chronic pain
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash. This acquisition will add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, aiming to expand care options for chronic pain sufferers. The deal is expected to close in the first half of Fiscal 2027, subject to regulatory approvals.
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Medtronic plc announced its intent to acquire SPR Therapeutics, Inc. for approximately $650 million. This acquisition will enhance Medtronic's Neuromodulation portfolio by adding temporary peripheral nerve stimulation (PNS) technology, specifically the SPRINT® PNS System, to provide earlier intervention options for chronic pain sufferers. The transaction is expected to close in the first half of Medtronic's Fiscal Year 2027.
Medtronic PLC $MDT is Lazard Freres Gestion S.A.S.'s 10th Largest Position
Lazard Freres Gestion S.A.S. has significantly increased its stake in Medtronic PLC, making it the 10th largest position in its investment portfolio. Medtronic reported strong quarterly results, surpassing analyst expectations with $1.36 EPS and $9.02 billion in revenue, and continues to be an attractive income stock with a 47-year streak of dividend increases. The company's revenue rose 5.8% year over year, and it maintains a moderate buy rating from analysts with an average price target of $107.80.
HighTower Advisors LLC Has $138.80 Million Stock Holdings in Medtronic PLC $MDT
HighTower Advisors LLC reduced its stake in Medtronic PLC by 1.1% in the fourth quarter, now holding 1,444,921 shares valued at $138.80 million. Despite this, other major institutional investors like Vanguard Group Inc., State Street Corp, and Bank of New York Mellon Corp significantly increased their holdings in the medical technology company. Wall Street analysts currently rate Medtronic as a "Moderate Buy" with an average target price of $107.80.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $8.37 Million in Medtronic PLC $MDT
Fideuram Intesa Sanpaolo Private Banking S.P.A. has acquired a new stake of 87,140 shares in Medtronic PLC, valued at approximately $8.37 million. This investment highlights continued institutional interest in Medtronic, with 82.06% of the stock held by institutions and hedge funds. The medical technology company recently reported strong quarterly earnings, exceeding analyst expectations with $1.36 EPS on $9.02 billion in revenue, and maintains a "Moderate Buy" consensus rating among analysts.
Stryker’s Amplitude Deal Extends Peripheral Vascular Reach And Investor Debate
Stryker (NYSE:SYK) has announced its acquisition of Amplitude Vascular Systems for up to $835 million, integrating next-generation hydraulic intravascular lithotripsy technology into its peripheral vascular portfolio. This strategic move aims to enhance Stryker's presence in treating peripheral arterial disease. The deal has generated investor interest, particularly given Stryker's recent mixed stock performance, highlighting a push towards business expansion and capital allocation decisions.
WisdomTree US SmallCap Dividend Fund Faces Payout Durability Questions
The WisdomTree U.S. SmallCap Dividend Fund (NYSEARCA:DES) distributes monthly dividends, but their consistency and long-term sustainability are under scrutiny due to significant monthly fluctuations and a fund design heavily weighted in cyclical sectors. While macroeconomic strength, evidenced by robust corporate profits, currently supports the underlying companies' ability to sustain payouts, investors relying on these distributions are advised to focus on annualized totals rather than inconsistent monthly figures. The fund's unique index weighting, based on the absolute dollar amount of dividends paid, restricts its ability to shift to safer defensive equities during market stress, posing a potential vulnerability.
Medtronic plc stock (IE00BTN1Y115): New products, pricing, and growth outlook
This article discusses Medtronic plc (IE00BTN1Y115), a major global medical technology company relevant to U.S. investors due to its role in American healthcare, diverse product portfolio, and exposure to structural healthcare spending. It highlights the company's core business model, key revenue drivers in cardiovascular, neuroscience, diabetes, and surgical technologies, and its sensitivity to U.S. policy and procedure volumes despite being Irish-listed. The piece emphasizes Medtronic's position as a broad-based medtech holding for investors seeking exposure to durable healthcare demand and innovation.
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the Jefferies Global Healthcare Conference. Chairman and CEO David Hochman will engage in a fireside chat and one-on-one investor meetings, discussing the company's high-impact technologies like AVIM Therapy and Virtue® Sirolimus AngioInfusion™ Balloon, both currently in pivotal clinical trials for significant global market opportunities.
Robotics expert Brian Miller on product development, AI and what he learned at Intuitive
Brian Miller, former Intuitive EVP and chief digital officer, shares insights on product development, understanding customer needs, and the role of AI in surgical robotics, drawing from his extensive experience. Now CEO of Sovato, Miller emphasizes the importance of critical thinking, deep customer observation, and responsible use of AI and data in medical device innovation. He also touches on making the most of intraprocedural data and addressing potential "deskilling" concerns with advanced technologies.
Medtronic PLC stock outperforms competitors on strong trading day
Medtronic PLC (MDT) stock advanced 1.63% to $78.58 on Tuesday, outperforming its competitors despite a general market downturn. The S&P 500 Index and Dow Jones Industrial Average both experienced declines. This marks the second consecutive day of gains for Medtronic PLC.
Medtronic, BD name new leaders
Medtronic is promoting Kweli Thompson to president of its neuroscience portfolio, effective June 1, replacing Brett Wall. Separately, BD has appointed Peter Menziuso as president of its interventional business, also starting June 1. Menziuso joins BD from Johnson & Johnson Vision and is expected to drive growth in BD's interventional sector, which generated $1.36 billion in revenue last quarter.
How New Aficamten Phase 3 Data and Equity Raise Will Impact Cytokinetics (CYTK) Investors
Cytokinetics (CYTK) recently announced positive Phase 3 data for its cardiac drug aficamten, covering both obstructive and non-obstructive hypertrophic cardiomyopathy. Despite robust Q1 2026 revenue of US$19.36 million, the company reported a net loss of US$206.03 million, necessitating a US$700 million equity raise to fund commercialization and trials. This data and capital infusion bolsters confidence in aficamten's market potential, but investors should remain aware of ongoing dilution risks due to continued losses.
Scott R. Ward, ex-Medtronic leader, joins Merit Medical board
Merit Medical Systems (NASDAQ: MMSI) announced that shareholders elected Scott R. Ward to its Board of Directors for a three-year term at their annual meeting on May 19, 2026. Ward, an executive with over 40 years of experience in the healthcare and medical device industry, including senior roles at Medtronic and as CEO of Cardiovascular Systems, will serve on the Board’s Governance and Sustainability and Finance and Operating Committees. This appointment is expected to provide valuable strategic insight and support the company's long-term growth and innovation goals.
Jefferies healthcare fireside chat to feature Orchestra BioMed CEO
Orchestra BioMed (Nasdaq: OBIO) announced its participation in the Jefferies Global Healthcare Conference, where Chairman and CEO David Hochman will engage in a fireside chat on June 4, 2026, and host one-on-one investor meetings. The company is advancing two flagship product candidates, AVIM Therapy and Virtue SAB, both in pivotal clinical trials with significant market potential and FDA Breakthrough Device Designations. Recent milestones include securing $35 million in strategic capital and reporting Q1 2026 results.
What Insulet (PODD)'s Buybacks, Raised Guidance and Riyadh Hub Mean For Shareholders
Insulet Corporation recently reported strong Q1 results with $761.7 million in revenue and $91.1 million in net income, confirmed upgraded 2026 revenue growth guidance, completed a significant share repurchase, and established a regional headquarters in Riyadh. These moves aim to strengthen the company's financial position, signal confidence in its growth trajectory, and expand its reach into international diabetes markets, particularly focusing on recurring revenue from its Omnipod franchise. The success of the Riyadh hub will be crucial for its international expansion strategy.
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity?
Abbott Laboratories (ABT) stock has seen a significant decline over the past year, but a recent analysis by Simply Wall St suggests it may now be undervalued. Using a Discounted Cash Flow (DCF) model and Price-to-Earnings (P/E) ratio comparison, the article indicates that ABT could be trading at a substantial discount to its intrinsic value. Investors are encouraged to explore different valuation narratives to form their own conclusions about the stock's potential.
Medtronic PLC $MDT Shares Acquired by Handelsbanken Fonder AB
Handelsbanken Fonder AB increased its stake in Medtronic PLC by 7.9% in the fourth quarter, now holding 669,085 shares valued at approximately $64.3 million. Medtronic reported strong quarterly earnings of $1.36 per share on revenues of $9.02 billion, exceeding estimates, and declared a quarterly dividend of $0.71 per share. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $107.80.
BioCardia Reports Promising CardiAMP Cell Therapy Data in Q1 2026 Conference Call
BioCardia discussed positive results for its CardiAMP Cell Therapy for ischemic heart failure during its Q1 2026 conference call. Blinded echocardiography data from the CardiAMP Heart Failure trial, analyzed by Yale University, showed treated patients maintained stable heart volumes, unlike control subjects. The therapy, which has FDA breakthrough designation and Medicare reimbursement, showed statistically significant benefits in a subgroup with elevated heart stress biomarkers, aligning with a composite endpoint for improved long-term outcomes.
Baxter Board Size Reset Puts Governance Changes In Focus For Investors
Baxter International (NYSE:BAX) recently received shareholder approval to amend its certificate of incorporation and bylaws, adjusting the framework for its board size to between seven and twelve directors. This governance change is viewed as a tool to reshape oversight and potentially bring in fresh expertise, especially in light of the company's weak share performance over the past five years. Investors are now watching for future announcements regarding new director appointments, committee reshuffles, or changes in capital allocation policies to assess how this flexibility will be utilized to address operational and financial challenges.
Medtronic stock (IE00BTN1Y115): focus on diabetes spin-off and latest quarterly results
Medtronic is strategically reshaping its portfolio by proposing a spin-off of its patient monitoring and respiratory interventions business into a new company named Empirion, aiming for a more focused approach on high-growth areas like cardiovascular and diabetes technologies. The company also reported solid quarterly financial results for fiscal 2025, with an emphasis on its strong performance in cardiovascular and neuroscience therapies. This move is designed to create two distinct businesses, enhancing strategic clarity and potentially altering the growth and risk profiles for Medtronic and its shareholders, especially for US investors who track the company closely due to its significant US market presence.
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
Medtronic (MDT) saw its stock price increase by 1.54% while the broader market declined. Despite this recent gain, the stock has dropped over 11% in the past month. The company is set to report earnings on June 3, 2026, with analysts anticipating a slight fall in EPS but growth in revenue, and currently holds a Zacks Rank of #4 (Sell).
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
Medtronic (MDT) saw a stock increase of +1.54% while the broader market declined, outperforming the S&P 500's daily loss. The company's stock has decreased by 11.65% over the past month, underperforming the Medical sector and the S&P 500. Investors are anticipating Medtronic's upcoming earnings report on June 3, 2026, with an expected EPS of $1.58 and revenue of $9.66 billion.
Boston Scientific Bets on Growth Through Strategic M&A Deals
Boston Scientific is focusing on strategic mergers and acquisitions to drive growth, expand into new areas, and strengthen its market position, exemplified by recent acquisitions in urology and pain management. The company also announced a definitive agreement to acquire Penumbra to enter fast-growing vascular segments. Meanwhile, peers like Abbott Laboratories and Medtronic are also pursuing significant M&A activities to expand their portfolios and market reach.
A Look At Zimmer Biomet (ZBH) Valuation After 2026 Buyback Boost And Higher EPS Guidance
Zimmer Biomet Holdings (ZBH) has announced an increase in its 2026 share repurchase expectations to US$1.0 billion and raised its adjusted earnings per share forecast, leading to recent positive share price movement despite a weaker year-long performance. The stock, currently trading at US$83.70 with an estimated intrinsic value of US$102.95, is considered undervalued, driven by expectations of improved sentiment and future growth from strategic investments in digital health and robotics. However, potential risks like flat pricing and integration challenges could impact margins.
Medtronic PLC stock outperforms competitors on strong trading day
Medtronic PLC (MDT) stock increased by 1.54% to $77.32 on Monday, outperforming the mixed stock market where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The company's stock closed 27.28% below its 52-week high of $106.33, achieved on November 26th. This strong trading day highlights Medtronic's performance relative to its competitors.
Senseonics Holdings Inc (FRA:6L60) Stock Price, Trades & News
This page provides a comprehensive overview of Senseonics Holdings Inc (FRA:6L60), a medical technology company specializing in continuous glucose monitoring systems. It details the company's current stock price, financial strength, growth, momentum, liquidity, and profitability ranks, along with a business description and upcoming events. The report also highlights three severe warning signs detected by GuruFocus for the stock.
10 New 5-Star Stocks This Week
Morningstar has identified 10 new US-listed stocks that have achieved a 5-star rating, including Amphenol and S&P Global, indicating they are significantly undervalued. These ratings are based on a stock's price, fair value estimate, and Uncertainty Rating. The overall US stock market is currently considered moderately undervalued, with 41% of covered stocks being undervalued by Morningstar analysts.
